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Abstract
Nanoparticle-based drug delivery systems have gained immense popularity due to their
ability to overcome biological  barriers,  effectively deliver drugs,  and preferentially
target  tissue.  In  this  chapter,  the  current  progresses  and  challenges,  especially
evaluation methods for nanodrugs in antitumor drug delivery systems, are summar‐
ized,  citing our works targeted at  cancer therapy.  It  includes four parts.  First,  the
principle,  advantages,  and significance of nanoparticle-based tumor targeting drug
delivery  system  are  presented.  Recent  developments  in  nanoparticle-based  tumor
targeting  drug  delivery  system  including  passive  targeting,  active  targeting,  and
stimuli-responsive systems/triggered release are introduced. Second, current formula‐
tions of nanoparticle-based drug delivery systems are described, including lipid-based,
polymeric and branched polymeric,  metal-based, magnetic,  and mesoporous silica.
Third, analytical techniques used for evaluating nanodrugs in vitro  and in vivo  are
emphatically described. Finally, disadvantages and challenges of nanodrug are also
discussed.
Keywords: nanoparticle, nanomicelle, tumor targeting, biological evaluation, nano‐
carrier, nanodrug, controlled-release, drug delivery system
1. Introduction
The last decade has witnessed enormous advances in the development and application of
nanotechnology in cancer detection, diagnosis, and therapy. A nanoparticle as per the National
Institutes of Health (NIH) guidelines is any material that is used in the formulation of a drug
resulting in a final product smaller than 1 micron in size. This chapter summarizes current
progresses and challenges, especially evaluation method for nanodrug in antitumor drug
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delivery systems, citing our works targeted at cancer therapy. This chapter mainly consists of
four parts. The first part presents the principle, advantages, and significance of nanoparticle-
based tumor targeting drug delivery system, including passive targeting, active targeting, and
stimuli-responsive systems/triggered release. The second part introduces the formulations of
nanocarriers, with emphases laid on lipid-based, polymeric and branched polymeric, metal-
based, and mesoporous silica. Some nanodrug carriers designed by us are introduced in this
part.  They  are  active  targeting  and  acid-responsible  nanoparticles,  novel  copolymers,
multifunctional acid-sensitive micelle,  and tumor microenvironment multiple responsible
nanodrug  release  system.  The  third  part  introduces  analytical  techniques  used  for  the
characterization of nanoparticles in vitro and in vivo, such as dynamic light scattering (DLS),
transmission electron microscope (TEM), scanning electronic microscopy (SEM), NMR, FTIR,
and UV-Vis were commonly used to characterize the nanodrugs. Techniques for cell biolo‐
gy, such as TEM, confocal microscopy, flow cytometry, Western blot, and immunohistochem‐
istry (IHC), were employed to evaluate target ability of nanodrugs in vitro. In vivo imaging
system, micro-CT, NMR, and drug biodistribution were used to assess the in vivo behavior
and  efficacy  of  nanodrugs.  Finally,  disadvantages  and  challenges  of  nanodrug  are  dis‐
cussed.  So far,  there  are  so  many papers  but  so  few nanodrugs in  cancer  therapy.  The
uncertainty and limitation of nanodrugs in pharmacology, toxicology, immunology, large-
scale  manufacturing,  quality  standard  setting,  and regulatory  issues  make  nanoparticle-
based tumor targeting delivery system have a long way to go.
2. Construction of nanoparticle-based tumor targeting drug delivery
systems and their targeting functionalities
2.1. Definition of nanoparticle-based drug delivery system and classification of targeting
functionalities
Increasing demand for and awareness of the applications of nanotechnology in medicine has
resulted in the emergence of a new fast-growing multidisciplinary area—nanomedicine.
Nanoparticles (NPs) serve as promising delivery system for various cargos such as drugs.
Drugs are incorporated in nanoparticles that have the ability to get through physiological
barriers and access the whole systemic circulation and thus are cleared less rapidly than free
drug.
Nanoparticle-based drug delivery system represents an opportunity to achieve sophisticated
targeting strategies and multi-functionality. They can increase the antitumor efficacy of
conventional chemo-therapeutics, decrease their systemic toxicity, prolong duration time in
systemic circulation, also present the following advantages, (1) help to overcome problems of
solubility and chemical stability of anti-cancer drugs; (2) protect anti-cancer drug from
biodegradation or excretion; (3) help to improve distribution of chemo therapeutics; (4)
designed to release their payload response to biological triggers; and (5) may decrease
resistance of tumors against anti-cancer drugs.
Micro and Nanotechnologies for Biotechnology260
Therefore, targeted delivery is of utmost importance in order to overcome current limitations
in cancer therapy. Recent developments in nanoparticle-based tumor targeting drug delivery
system could be concluded in four aspects, passive targeting, active targeting, and stimuli-
responsive systems/triggered release.
2.2. Passive targeting
Passive targeting is realized by specific porous loose structure of tumor vessels, which is easier
for nanoparticles to accumulate. This leaky cascularization is the so-called EPR effect (en‐
hanced permeability and retention effect), which allows migration of macromolecules up to
400 nm into tumor site [1–5]. For example, pegylated liposomal doxorubicin (Doxil®/Caelyx®)
and nab-paclitaxel (Abraxane®) are the first generation nanomedicine based on passive
targeting [6]. Numerous macromolecules and nanocarriers have shown to accumulate in tumor
via the passive targeting owing to the EPR effect [7, 8]. EPR-based chemotherapy is thus
becoming an important strategy to improve the delivery of therapeutic agents to tumors for
anticancer drug development, and macromolecular agents are potentially usefully for not only
cancer therapy, but for cancer diagnosis and imaging [9]. Although passive targeting ap‐
proaches form the basis of clinical therapy, they suffer from several limitations. Not all the
tumors exhibit EPR effects, and the permeability of vessels may not be the same throughout a
single tumor [10, 11]. For example, Kaposi sarcoma with fenestrated vasculature, nanomedi‐
cine therapeutics could passive target into tumors without any specific ligand attached to the
surface of the nanocarrier. However, heterogeneity of the tumor, such as different hypoxic
gradient, can severely impact on the efficacy of passive targeting delivery. Moreover, increased
interstitial fluid pressure (IFP) is another limitation of passive targeting, which reduces
convective transport, while the dense extracellular matrix hinders diffusion [12]. Finally,
though passive targeting could be used for delivering nanomedicine to certain solid tumor, it
does not prevent accumulation of nanocarriers in some organs with fenestrated endothelium,
for example, the liver and spleen [13].
Therefore, the development of nanomedicine drugs with active targeting functionalities is
certainly warranted. One way to increase the targeting efficacy of nanoparticle-based drug
delivery systems is to attach affinity ligands, such as antibodies [14], peptides [15], aptamers
[16] or small molecules such as folic acid and carbohydrates onto the surface.
2.3. Active targeting
Passive targeting allows for the efficient localization of nanoparticles within the tumor
microenvironment. Active targeting facilitates the active uptake of nanoparticles by the tumor
cells themselves. Nanoparticle-based drug delivery systems decorated with specific targeting
ligands will recognize and bind to target cells and then enter the cells through receptor
mediated endocytosis. In order to achieve high specificity, those receptors should be highly
expressed on tumor cells, but not on normal cells. In our previous studies, folic acid [17], LHRH
[18], HAb18 F(ab′)2 [19] and monoclonal antibody [14] have been conjugated on the nanopar‐
ticles surface to enhance their targeting efficacy. The active targeting nanoparticles first specific
bind to the receptor on the cell surface, then get internalized in small concave formed on the
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cell membrane. Small concave closed the opening to form endocytic vesicle, then early
endosome. The newly formed endosome is transferred to specific organelles, and drugs could
be released by acidic pH or enzymes [20–22]. This endocytosis procedure was also confirmed
in our recent research [14], which was illustrated by the schematic below (Figure 1).
Figure 1. Illustrative schematic representing the endocytosis procedure of the SiO2@AuNP delivery system after bind‐
ing to cell surface targets. Followed by escaping from the endosomes/lysosomes, the drugs were sequentially released
in cytoplasm to eliminate cancer cells. Confocal microscopy and TEM were introduced to testify the endocytosis and
endosomal escape procedure of SiO2@AuNP [14].
Among the potential targets for mAb-mediated nanoparticle delivery, human epidermal
growth factor receptor 2 (HER2) [23], epidermal growth factor receptor (EGFR) [24], transferrin
receptor (TfR) [25], and prostate-specific membrane antigen (PSMA) [26] have been extensively
investigated. Over the last several years, aptamers have quickly become a new class of
targeting ligands for drug delivery applications. Aptamer-based delivery systems of chemo‐
therapy drugs (e.g., doxorubicin, docetaxel, daunorubicin, and cisplatin), toxins (e.g., gelonin
and various photodynamic therapy agents), and a variety of small interfering RNAs were well
established during past years [27]. Small molecules such as folic acid were also been widely
used due to its inherent properties, which confer distinctive advantages and make it suitable
ligand for nanoparticle targeting [28].
Furthermore, active targeting of nanocarriers has shown the potential to suppress multidrug
resistance (MDR) via bypassing of P-glycoprotein-mediated drug efflux [29].
Although active targeting delivery systems looks promising, no one was currently approved
for clinical use. Moreover, nanodrugs currently under clinical development lack specific
targeting.
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2.4. Stimuli-responsive systems/triggered release
Although passive and active targeting has been widely investigated, it still cannot guarantee
sufficient high drug concentration in tumor site to achieve the complete eradication of tumors.
Sufficient and sustained therapy is on the demand of controlled and sustained release of
chemotherapeutics in tumor site. Therefore, it is highly desirable to design stimuli-responsive
controlled drug delivery systems (CDDSs), which could release drugs by responding to tumor
cell environmental changes, such as pH, temperature, glucose, adenosine-5′-triphosphate
(ATP), glutathione (GSH), and H2O2 [30].
Among these stimuli, change in acidity as an internal signal is particularly crucial for the
development of CDDSs that facilitate tumor targeting. Compared to the extracellular pH of
normal tissues at pH 7.4, the measured tumor extracellular pH (pHe) values of most solid
tumors range from pH 6.5 to 7.2. Moreover, changes in pH are also encountered once the
CDDSs enter cells via endocytosis where pH can drop as low as 5.0–6.0 in endosomes and 4.0–
5.0 in lysosomes. The pH gradient is caused by hypoxia that upregulates glycolysis, followed
by the production of lactate and protons in extracellular microenvironments [31]. pH-sensitive
CDDSs can be used for delivering anti-cancer drugs to specific cancer cells, enhancing cellular
internalization and rapid intracellular drug release. In order to increase the targeting activity,
ligand-modified pH-sensitive CDDSs have been used for tumor targeting [32, 33]. In our
previous study, many efforts have been made on several systems based on pH sensitive drug
release characteristics. For instance, (1) pyrrolidinedithiocarbamate (PDTC) and doxorubicin
Figure 2. Schematic of targeting approaches and drug release procedures of LHRH-PEG-PHIS-Dox/Dox-TAT mixed
micelles [18].
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(DOX) was codelivered by copolymer folate-chitosan (FA-CS) nanoparticles to achieve
targeted drug delivery, stimuli sensitive drug release, and to overcome multidrug resistance
(MDR). (2) A novel delivery system based on LHRH-PEG-PHIS-Dox/Dox-TAT acid-sensitive
micelles was developed, as shown in Figure 2. Such system could dissociate when responding
tumor extracellular pHe and release Dox-TAT. This system showed remarkable antitumor
efficacy and negligible systematic toxicity.
Higher concentration of GSH tripeptides is another important internal stimulus for rapid
destabilization of CDDSs inside cells to accomplish rapid intracellular release [34]. The
intracellular GSH concentration (1–10 mM) is substantially higher than extracellular levels
(2 μM in plasma), providing a mechanism for selective intracellular release [35]. Gold nano‐
particles were widely used for design GSH-triggered drug delivery systems. Its surface
monolayer is stable under most physiological conditions, thus providing a reservoir of
hydrophobic drugs, yet allowing controlled release by GSH though place exchange reactions
of thiols on gold nanoparticle surfaces. These Au nanoparticles systems, which are under
intensive study, display very intriguing properties, such as the precise control of intracellular
drug release triggered by GSH. However, despite their great potential, additional investiga‐
tions will be required to fully understand their pharmacokinetics, their interactions with the
immune system, and the extent of cytotoxicity due to the surface and the geometry of the gold
nanoparticles. Our research also focused on GSH-mediated drug release, such as siRNA [14]
(Figure 3) and miR-218 mimics [36] (Figure 4) release from AuCOOH. After endocytosis,
mediated by mAb198.3, the siRNA release process was illustrated by Figure 3. siRNA was
released by the place exchange of glutathione (GSH) [37], and different band shifts on the
denatured polyacrylamide gel page demonstrated the process of GSH-triggered siRNA
release. In the research based on FA-CS@AuCOOH nanoparticles, temozolomide was released
by diffusion due to FA-CS nanogel swelling, followed by miR-218 mimics was released by
place exchange of GSH in tumor cells, which was illustrated in Figure 4. The sequential release
of both chemo-drug and bio-drug exhibited significant synergistic effect against U87MG
glioblastoma cells.
Figure 3. siRNA release procedure of outer AuNP layer. Schematic illustration of siRNA release procedures via GSH
place exchange (A), confirmed by denatured SDS page (B) [14].
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Figure 4. Schematic of drug design and drug release schedule. GSH mediated miR-218 mimics release from AuNP was
emphasis by blue box [36].
Temperature is also a typical trigger at the tumor site, which could be exploited for drug
delivery systems design [37, 38]. Thermo-responsive drug delivery is among the most
investigated stimuli-responsive strategies. Usually, thermo-responsive nanocarriers were
governed by a nonlinear sharp change with temperature, following by the release of the drug
response to the temperature change. Ideally, thermo-responsive drug delivery systems should
stay stable at body temperature (37°C) and rapidly release the payload within a locally heated
tumor (40–42°C) to counteract rapid blood-passage time and washout from the tumor [38].
Poly(N-isopropyl acrylamide), PNIPAM was one of the most widely investigated thermo-
sensitive materials, which exhibit a lower critical solution temperature. When surrounding
temperature is above its LCST, the PNIPAM nanocarriers will shrink and push out the payload.
For liposomes, thermos responsiveness usually arises from a phase transition of the constituent
lipids and the associated conformational variations in the lipid bilayers [38, 39]. Thermo-
responsive nanoparticle drug delivery systems typically present a lower critical solution
temperature (LCST) at which they undergo coil-to-globule phase transitions. Thermo-sensitive
liposomes usually composed of polymers with low LCST, which attached to lipid membranes
due to hydrophobic interactions. The liposomes shrink to dehydrate and collapse, when the
temperature achieve LCST, promoting drug release. By adjusting monomers types and ratio,
polymer LCST can be tuned to different values, which could be used for controlling drug
release at different environments [39].
ATP is a new member of physiological triggers to achieve “on-demand” therapeutic delivery
with several merits, for example, high intracellular ATP concentration and sharp concentration
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contrast between intracellular and extracellular environment make ATP a robust trigger signal
to reduce premature drug release before cellular uptake and enhance intracellular accumula‐
tion of drugs [40]. ATP-triggered drug release system provides a more sophisticated drug
delivery system, which can differentiate ATP levels to facilitate the selective release of drugs.
Polymeric nanocarriers functionalized with an ATP-binding aptamer-incorporated DNA
motif can selectively release the intercalating doxorubicin via a conformational switch when
in an ATP-rich environment [41]. However, since the ATP binding modules are basically DNA
or protein, potential concerns for immunogenicity from the components need to be addressed
before clinical translations.
Glucose-responsive nanoparticles were widely investigated for insulin delivery [42]. Glucose
nanosensors are being incorporated to precise and accurate tracking blood glucose levels. Also,
they provide the guide for glucose-responsive nanoparticles which better mimic the body’s
demand for insulin. Besides, glucose-sensitive self-assembly is relevant for the application of
anticancer therapeutic drug delivery. Since cancer cells metabolize differently than normal
cells, glucose accumulate faster in tumor site than normal tissues and circulation [43–45].
Accumulation of glucose analogue 18fluoro-2-deoxy-d-glucose (18FDG) is 3.3–4.7 times greater
for tumor than normal liver [46, 47]. A novel approach for glucose-triggered anticancer drug
delivery from the self-assembly of neutral poly (vinyl alcohol) (PVA), and chitosan was been
investigated by Satish Patil research group. This system could release glucose controllable by
disintegration of layer by layer polymers. The capsules size and shape can be tuned because
of physically cross-linked PVA hydrogel inside the multilayer. Because of the presence of
borate in multilayer wall, the encapsulated drugs could be release programmable by different
glucose concentration. The borate mediated self-assembly of PVA hydrogel and chitosan
provide promising platform for intelligent anti-cancer drug delivery. The in vivo studies are
under going in their laboratory [48].
Reactive oxygen species (ROS) play important roles in a variety of physiological and patho‐
physiological processes [49]. Moreover, many types of cancer cells exhibit high level of ROS
stress [50]. An increase of H2O2 at cellular levels characteristic for cancer cells, which is a major
component of ROS and a common marker for oxidative stress, plays a key role in carcinogen‐
esis [51]. Thus, intracellular H2O2 in cancer cells was utilized as tumor site stimulus for drug
delivery in cancer therapy. Synergistic release of anticancer drugs and O2 can be achieved in
an H2O2-responsive nanocarrier incorporated with catalase. Such a system demonstrated
improved therapeutic efficacy against cisplatin resistant cell lines which often appear to be in
hypoxia [52]. However, the most challenging problem for engineering ROS-controlled-release
systems is to improve the responsive sensitivity to ROS species, because of low concentration
and very short half-lives in most cellular. Although there are increasing number of ROS-
controlled release systems have been reported, development of highly sensitive nanocarriers
which are specifically responsive to physiological levels of ROS are highly desired.
Till now, no optimized targeting drug delivery platform has been announced. Each has its own
advantages and flaws, even for those under preclinical or clinical testing. It might be possible
that the combination sequential drug delivery system design could be more effective to precise
drug delivery, paving the way for a more effective personalized therapy.
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3. Nanoparticlated formulation-based drug delivery systems
What is such drug delivery systems composed of? Currently, many formulations of nanocar‐
riers are utilized including lipid-based, polymeric and branched polymeric, metal-based, and
mesoporous silica.
3.1. Lipid-based nanocarriers
The formulation of lipid-based nanomedicines against cancer has been hypothesized to
improve drug localization into the tumor tissue and to increase the anticancer efficacy of
conventional drugs, while minimizing their systemic adverse effects [53]. An ideal multifunc‐
tional lipid-based nanoparticle drug delivery system with targeting and triggering drug
release functions should be composed of a matrix phospholipid, a destabilizing phospholipid,
conjugation lipid, ligand attached, and a cell death marker. Chemotherapeutics and imaging
agents were loaded in nanoparticles in aqueous phase [54]. Among various lipid-based
formulations, classical examples are “liposomes,” which primarily consist of phospholipids
(major components of biological membranes) and have been extensively studied [55]. Prof.
A.D. Bangham of the United Kingdom first published preparation of liposomes with entrap‐
ped solutes. Then, many scientists present a well-studied class of drug carriers generally
characterized by the presence of a lipid bilayer that is primarily composed of amphipathic
phospholipids [54].
3.2. Polymeric and branched polymeric nanocarriers
Polymer-based nanomedicine for improvement in efficacy of cancer therapeutics has been
widely explored, including polymeric nanoparticles, polymer micelles, dendrimers, polymer‐
somes, polyplexes, polymer-lipid hybrid systems, and polymer-drug/protein conjugates.
Polymeric nanoparticles are defined by their morphology and composition. The therapeutic
agent is either conjugated to the nanoparticles surface, or encapsulated and protected inside
the polymeric core [56]. These polymeric nanoparticles are capable of loading wide range of
drugs for a sustained or controlled release at tumor sites to provide enhanced antitumor
efficacy with minimal systemic side effects. Also, these nanoparticles protect drugs from their
rapid metabolism during systemic circulation and clearance by the liver, kidney, and reticu‐
loendothelial system, which further improves drug’s stability and target specificity [3, 57]. In
recent years, major branch of our research was based on multifunctional poly(β-L-malic acid)-
based nanoconjugates [18]. This nanoconjugate with a pH-dependent charge conversional
characteristic was developed for tumor-specific drug delivery. As shown in Figure 5, nano‐
conjugates minimize nonspecific interactions with serum components and change the surface
charge of nanoconjugates in response to the tumor acidity (pHe), leading to promoted cell
internalization by the combination of electrostatic absorptive endocytosis and receptor-
mediated endocytosis.
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Figure 5. Schematic illustration of the stealth property and promoted tumor cell uptake of nanoconjugates (A) and
DOX-loaded nanoconjugates (DOX/HDPEPM) (B). DMA, 2,3-dimethylmaleic anhydride; DOX, doxorubicin;
HDPEPM, nanoconjugate formed by covalent attachment of fragment HAb18 F(ab′)2 and 2,3-dimethylmaleic anhy‐
dride to polyethylenimine-modified poly(β-L-malic acid); PEI, polyethylenimine; PMLA, poly(β-L-malic acid) [19].
3.3. Metal-based nanocarriers
Metal-based inorganic nanoparticles with monodispersity have been extensively studied for
imaging using magnetic resonance and high-resolution superconducting quantum interfer‐
ence devices for cancer therapy [58]. Among all inorganic nanoparticles, gold nanoparticles
were mostly explored for anti-tumor therapeutics delivery, due to its surface properties, strong
affinity to thiol and amine functionalities and relative non-toxic nature [59]. Gold nanoparticles
have been used mostly as a probe for electron microscopy and as a delivery vehicle for
biomolecules. Also, super paramagnetic iron oxide nanoparticles (SPION) and gadolinium
chelates are gaining interest as MRI agents [60]. Magnetic nanoparticles (MNPs) are also
gaining clinical importance as MRI contrast materials, such as ferumoxides and ferumoxtran;
approved by the FDA for detecting solid tumors [61]. Gadolinium-conjugated TiO2-DNA
oligonucleotide nanoconjugates show prolonged intracellular retention period and T1-
weighted contrast enhancement in magnetic resonance images. Moreover, the increased
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retention time, Gd accumulation, and intracellular delivery may find its use in Gd neutron-
capture cancer therapy [62]. Silver and platinum nanoparticles are also used for therapeutics
delivery applications. Scientists at UC Santa Barbara presented a class of AgNPs that are
exceptionally bright and photostable, carry peptides as model targeting ligands, can be etched
rapidly and with minimal toxicity in mice, and that show tumor uptake in vivo [63]. These
results illustrate how plasmonic nanoprobes based on etchable Ag cores will be a powerful
tool in studies of targeted uptake and trafficking from a subcellular to tissue level. Nanopar‐
ticles built from platinum cross-linker present a novel platform for anti-tumor drug delivery.
As novel cross-linker, platinum Pt (IV) diester derivative agglomerates PEG-based brush-arm
star polymers (BASPs) with tunable structures was used for delivery several kinds of antitumor
drug, such as doxorubicin, camptothecin, and cisplatin. The cross-linker disintegrates when
reduced by glutathione, which is abundant inside cells, to release the drugs bound covalently
to the star polymers. This process is well-controlled as the sizes and Pt-loading of the narrowly
dispersed stars is tunable by variables such as brush length and cross-linker loading. Further‐
more, in vitro and in vivo assays demonstrate an efficacy of anticancer activity and low off target
toxicity [64].
3.4. Mesoporous silica–based nanocarriers
Multifunctional mesoporous silica nanoparticles (MSNs) are widely used as universal
platform for drug delivery [65]. Highly attractive features, such as high internal surface area
and pore volume, tunable pore sizes, colloidal stability, and the possibility to specifically
functionalize the inner pore system and/or the external particle surface, make MSNs a
promising and widely applicable platform for diverse biomedical applications including
bioimaging for diagnostics [66], biosensing [67], biocatalysis [68], bone repair and scaffold
engineering [69], and drug delivery [70]. For applications of multifunctional MSNs as drug
delivery systems in future and further advanced in clinical trials, they should be designed with
two different ways. One approach is to build up systems which could release drug response
to stimuli already present in the organism, such as lower pH values and redox potential in
endosomes (for triggered release functions). The other approach would rely on the use of
external triggers (in combination with internal stimuli) to control the drug release behavior,
for example, to release payloads in certain location of tissues or in certain time. Recent studies
focus on the ultimate combination of diagnostic and therapeutic capabilities in the multifunc‐
tional mesoporous nanoparticles, such that the nanocarrier uses diagnostic information to
control or tune its therapeutic actions [65]. Stimuli-free programmable drug release for
combination chemo-therapy has been also investigated by Dr. Fan in our research group. In
her previous work, she demonstrated programmed delivery of both chemotherapeutics and
biodrug with tumor targeting efficacy by introducing SiO2-based self-decomposable nanopar‐
ticles. The programmable drug delivery is realized by adjusting drug loading ratios and
concentration with external stimuli-free characteristics [71]. The present system provides a
simple and feasible system for design targeting and combination chemotherapy with pro‐
grammed drug release (Figure 6).
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Figure 6. Schematic of the SiO2 NP delivery system, its targeting scheme, and sequential drug release process. (a) Drug
design of the mAb198.3-SiO2-Dox/MB NP, (b) Targeting scheme of the NP drug (c) Multi-drug release process in a se‐
quential manner [71].
4. Analytical techniques used for characterization of nanoparticles in
vitro and in vivo
When materials are reduced at nanoscale dimensions, they show unique properties that are
different from their massive counterparts. In order to characterize nanoparticles, their particle
size, size distribution, morphology, composition, surface chemistry, and reactivity are
important factors that need to be defined accurately. These properties make nanomaterials a
suitable carrier for unique sensing applications and, at the same time, they may also create
complications during the characterization process. Choosing the right method for the charac‐
terization of nanoparticles is a challenging task since one should be aware that each technique
has its own limitations. The characterization of nanoparticles is carried out through various
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techniques such as dynamic light scattering (DLS), scanning electron microscopy (SEM),
transmission electron microscopy (TEM), NMR, FTIR, UV-Vis spectroscopy [72]. Techniques
for cell biology, such as TEM, confocal laser scanning microscopy (CLSM), and flow cytometry,
were employed to evaluate target ability of nanodrugs in vitro. In vivo imaging system and
drug biodistribution were used to assess the in vivo behavior and efficacy of nanodrugs.
4.1. Dynamic light scattering (DLS) analysis
The size of nanoparticles is one of the key parameters that influence the interaction between
nanoparticles and cells, which influenced cellular uptake [73, 74]. DLS is the most suitable
technique to determine the particle size of nanoparticles (Figure 7).
Figure 7. Particle size and size distribution of nanoparticles.
DLS is a technique in physics that can be used to determine the size distribution profile of small
particles in suspension or polymers in solution, by measuring the random changes in the
intensity of light scattered based on dynamic Brownian motion of the suspended particle. This
technique is also called photon correlation spectroscopy (PCS) and quasi-elastic light scattering
(QELS). The latter terms are more common in older literature. Typical applications are
emulsions, micelles, polymers, proteins, nanoparticles or colloids. In general, the technique is
best used for submicron particles and can be used to measure particle with sizes less than a
nanometer. In this size regime (microns to nanometers) and for the size measurement (but not
thermodynamics), the distinction between a molecule (such as a protein or macromolecule)
and a particle and even a second liquid phase (such as in an emulsion) becomes blurred.
There are several advantages associated with DLS: simplicity; sensitivity and selectivity to
NPs; short time of measurement; and the fact that calibration is not needed. Therefore, this
technique is increasingly used for nanoparticle characterization in various science and
industry fields [75, 76]. However, some problems are encountered when measuring samples
with larger size distributions or multimodal distributions [77]. If the measured colloid is
monodispersed, the mean diameter of the nanoparticles can be determined using the DLS
technique. For polydispersed colloids, there is a risk during the DLS measurement, as small
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particles can be screened by bigger particles, since bigger particles have more scattering
property .
Some DLS instrument can measure not only particle size, but also Zeta potential at the same
time [78]. Zeta potential is the surface charge of nanoparticles in solution (colloids). Nanopar‐
ticles have a surface charge that attracts a thin layer of ions of opposite charge to the nano‐
particles surface. This double layer of ions travels with the nanoparticle as it diffuses
throughout the solution. The electric potential at the boundary of the double layer is known
as the Zeta potential of the particles and has values that typically range from +100 mV to
−100 mV. Zeta potential is an important tool for understanding the state of the nanoparticle
surface and predicting the long-term stability of the nanoparticle (Figure 8).
Figure 8. Zeta potential of different DOX-loaded nanoconjugates at (A) pH 7.4 and (B) pH 6.8 (n = 5). At pH 7.4, no
charge-conversional behaviors were observed. When the pH was decreased from 7.4 to 6.8, both DOX/DPEPM and
DOX/HDPEPM nanoconjugates showed a significant charge conversion [19].
4.2. Transmission electron microscope (TEM) and scanning electronic microscopy (SEM)
Particle morphology is another important parameter for the characterization of nanoparticles,
and this is achieved with the help of microscopic techniques such as SEM and TEM. Both
techniques produce a resolution that is a thousand times greater than the optical diffraction
limit. SEM uses a beam of high-energy electrons to produce a variety of signals that contain
information about the sample’s surface composition, topography, and other properties such
as electrical conductivity. We can analyze the sample at various times because X-rays generated
by SEM do not lead to a loss of volume of the sample. However, electron microscopy creates
a risk of radiation damage that is caused by the electron beam, which leads to the generation
of free radicals. The diffusion of free radicals and the loss of mass may cause physical damage
to the sample [78]. Also, TEM suffers from the limitations of poor contrast, especially in the
event of peptide/protein nanoparticles and their conjugates. Besides particle morphology,
TEM and SEM could also be used to study the physical size of nanoparticles (Figure 9).
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However, there are some disadvantages associated with TEM and SEM: time consuming, high
operator fatigue, few particles examined.
Figure 9. TEM and SEM micrographs of blank and drug-loaded nanoparticles (a) TEM of blank nanoparticles; (b) TEM
of drug-loaded nanoparticles; (c) SEM of blank nanoparticles; (d) SEM of drug-loaded nanoparticles [79].
4.3. NMR, FTIR, and UV-Vis spectroscopy
NMR, FTIR, and UV-Vis spectroscopies are primary methods for determining the structure of
compounds. They are also used in analyzing the structure of nanoparticles, especially to
confirm the modification of polymer carriers. These are simply done and rapid. They can be
combined to give overlapping information. NMR spectroscopy is one of the most nondestruc‐
tive techniques in elucidating molecular structure as well as understanding the molecular
dynamics of organic, organometallic, inorganic, polymeric, and biological molecules (Figure
10). It can be also used in nanoparticle size determination and nanoparticle surface study [80,
81]. IR spectra can be used to provide information on the functional groups as well as the
structure of a molecule as a whole. UV-Vis spectra have broad features that could provide only
limited information of structure but very useful for quantitative measurements.
Figure 10. 1H NMR spectra of (a) PMLA, (b) PEI-PMLA (PEPM), (c) DOX/PEPM, and (d)DOX/DPEPM. DMSO was
used as the solvent [19].
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The ability to enter target cell efficiently is a key character of nanoparticles. Techniques for cell
biology, such as confocal microscopy, flow cytometry, were employed to evaluate target ability
of nanodrugs in vitro.
4.4. Confocal laser scanning microscopy (CLSM)
CLSM is a technique for obtaining high-resolution optical images with depth selectivity. The
key feature of CLSM is its ability to acquire the in-focus images from selected depths, a process
known as optical sectioning. It could be used to observe the cellular uptake of fluorescence
labeled nanoparticles, as well as nanoparticles-cell interaction (Figure 11).
Figure 11. Confocal images of Colo 205 cells incubated with AuCOOH(Cy5)_isotype (negative control) and Au‐
COOH(Cy5)_mAb198.3 and nucleus stained with DAPI. Incubated time: 15 min, 30 min and 4 h. (Blue fluorescence is
associated with DAPI, and red fluorescence is associated with Cy5). Scale bar at 20 μm [36].
4.5. Flow cytometry
Flow cytometry is a laser-based, biophysical technology employed in cell counting, cell sorting,
biomarker detection, and protein engineering, by suspending cells in a stream of fluid and
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passing them by an electronic detection apparatus. It is extensively used in research for the
cell apoptosis and fluorescence quantitative analysis of nanoparticles to evaluate its targeting
efficacy (Figure 12).
Figure 12. FACS analysis of A2780/DoxR cells incubated for 1 h at 37°C with untreated cell as control (A, E), LHRH-
PEG-PHIS-Dox/Dox-TAT (B, F), LHRH-PEG-PHIS-Dox/Dox (C, G) and LHRH-PEG-PHIS-Dox (D, H) at pH 7.4 or pH
6.8, respectively [18].
4.6. In vivo imaging system
The ability of nanoparticles to achieve high, local concentrations of drugs at a target site
provides the opportunity for improved system performance and patient outcomes along with
reduced systemic dosing. Current technologies for tumor imaging, such as in vivo imaging
system, are able to yield high-resolution images for the assessment of nanoparticles uptake in
tumors at the microscopic level; a microscopic visual representation of a biological component
inside the body [82]. The imaging procedure often utilizes a variety of diagnostic tools to
provide insight regarding disease states, molecular characterization, and biological processes
(Figure 13).
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Figure 13. In vivo imaging of Colo 205 tumor bearing mice. Fluorescent signal captured by IVIS Lumina Imaging Sys‐
tem in tumor bearing mice after injection with AuCOOH(Cy5)_ mAb198.3 (a), AuCOOH(Cy5)_ isotype (b), and
mAb198.3_Cy5 (c) for 24 h. Luminescent image of resected organs from Colo 205 tumor-bearing mouse injected with
AuCOOH(Cy5)_ mAb198.3 (d), AuCOOH(Cy5)_ isotype (e), and mAb198.3_Cy5 (f) for 24 h [36].
4.7. Drug biodistribution analysis
Another method to assess the in vivo behavior and efficacy of nanodrugs is drug biodistribution
analysis. This is a method of tracking where drugs of interest travel in an experimental animal
or human subject by the determination of drug concentration in targeted site and other organs.
5. Disadvantages and challenges of nanodrug
Nanodrug since its emergence has proved to be promising novel drug delivery system. In
recent years, great progress was achieved in making drugs owning the characteristics of
targeted and controlled release via nanotechnologies. However, there are some challenges in
the use of large size materials in drug delivery. Some of these challenges are poor targeting
and therapeutic effects, sustained and targeted delivery to site of action, poor bioavailability,
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generalized side effects, in vivo stability, intestinal absorption, and plasma fluctuations of drugs
[83]. Taking the active targeting strategy as an example, it is not always as effective as expected.
The main mechanism behind active targeting is the recognition of the ligand by its target
substrate. But because of the heterogeneity of tumor cells, receptors on the surface of tumor
cells are different from cell to cell. Therefore, the interaction between cell receptors and ligands
linked to nanoparticles becomes unreliable, which the nanoparticles was relied on to enter into
the cell. This results in poor targeting and therapeutic effects in some cases [84]. Besides,
distribution through the tumor is severely limited by its relatively large size which slows
diffusion and may become trapped in the ECM. Other obstacles with nanocarriers that must
be concerned include complicated synthesis, in vivo aggregation and recognition by the
reticuloendothelial system leading to high clearance. This is further complicated when the
therapeutic is covalently attached to the drug carrier as in the case of many polymers. Finally,
most studies are at the basic research stage at present. Since it was unknown about environ‐
mental influence and genetic effect of novel nanomaterials, much works and a long process
for acceptance by public were needed for more nanodrugs to be used in clinic.
To reach the promise of nanodrugs, it is necessary to take a step back and look at the problems
facing drug delivery as a whole rather than designing around only one or two obstacles.
Incremental designs may not be sufficient to accomplish the task of treating cancer effectively.
Instead, a revolution in concept is needed. Nanodrug delivery system with simple synthesis
routes and high targeting/therapeutic efficacy may point the way out.
So far, there are so many publications but so few nanodrugs in cancer therapy [85]. The
uncertainty and limitation of nanodrugs in pharmacology, toxicology, immunology, large-
scale manufacturing, and regulatory issues make it become an important research field in
nanoparticle-based tumor targeting delivery system. And how we can overcome these
difficulties, it is a long way to go.
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